Related Experiment Video
Updated: May 24, 2025
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Nomogram for Predicting Severe Abdominal Pain During Percutaneous Radiofrequency Ablation for Hepatocellular
Jin-Ming Tian1, Jianan Zhang1, Hang Liu1
1Department of Interventional Radiology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, People's Republic of China.
Objective:
To develop and validate a nomogram for identification of hepatocellular carcinoma (HCC) patients unsuitable for percutaneous radiofrequency ablation (RFA) due to severe abdominal pain.
Methods:
In this retrospective study, 530 patients with HBV-HCC underwent RFA between February, 2014, and April, 2024, and treated in the affiliated hospital of Changhai Hospital, Naval Medical University. Patients were divided into a modeling group (373 cases) and a validation group (157 cases) at a 7:3 ratio. Pain severity during the heating process of the radiofrequency ablation system was assessed using the Visual Analog Scale (VAS). Logistic regression was used to determine risk factors for severe pain, based on which a nomogram was developed.
Results:
Key predictors of severe abdominal pain included tumor distance to capsule <1cm, tumor distance to portal vein <1cm, and history of transarterial chemoembolization (TACE) (P<0.05). The nomogram showed excellent predictive performance with an AUC-ROC of 0.756 for the modeling group and 0.714 for the validation group.
Conclusion:
Tumor distance to capsule, tumor distance to portal vein, and TACE history are independent factors influencing severe abdominal pain during radiofrequency ablation in HBV-HCC patients. The nomogram effectively identifies HCC patients at risk of severe pain during RFA, facilitating doctors to decide on better alternative locoregional therapies.
